Navigation Links
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Date:6/25/2009

or chewed, the naltrexone would be released, mitigating the euphoric effect of the morphine. The clinical significance of the degree of these reductions has not been established and there is no evidence that the naltrexone in EMBEDA(TM) reduces the abuse liability of EMBEDA(TM).

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.

Forward Looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to King's planned presentations; statements pertaining to the Company's expectations for its novel pain treatment candidates and potential prospective physician utilization of these candidates; and statements pertaining to the Company's expectations regarding the FDA's review of the Company's NDAs for Acurox(R) (oxycodone hydrochloride and niacin) tablets and Embeda(TM). These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause actual results to differ materially from the forward-looking statements include dependence on King's ability to conduct its presentations as planned; dependence on the Company's ability to con
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... N.Y., Feb. 6, 2012 /PRNewswire-iReach/ -- SalesCongo ... announced today it has named Kenneth R. Kaisen as its ... as a technology industry veteran with over 25 years of ... Vertis Communications, a marketing communications company. He was previously CEO ...
... (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, ... presentation on the Company at the UBS 22nd Annual Global ... EST at the Grand Hyatt New York, New York City. ... Cambrex website http://www.cambrex.com in the Investors section of ...
Cached Medicine Technology:SalesCongo Names Ken Kaisen CEO 2
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part of ... people, in 2008 he suffered extreme financial hardship and lost ... carefully studied the difference between people who have sustainable and ... the knowledge he acquired, he was able to use what ... but also grow his clients' personal and financial assets while ...
(Date:7/30/2014)... WHAT: , Resistance to artemisinin, the main drug ... Asia, among the Plasmodium falciparum ( ... and is likely caused by a genetic mutation ... artemisinin-based combination therapyas opposed to a standard three-day ... cases, according to findings published today in the ...
(Date:7/30/2014)... 2014 Volunteers from the Church of ... abuse this summer with massive distribution of Truth ... find these volunteers on Strøget, the famous Copenhagen walking ... its shopping and its ambiance, some quarter of a ... summer day. , These activities are part of ...
(Date:7/30/2014)... Pennsylvania (PRWEB) July 30, 2014 Visitors ... have contributed over $8,500 to ensure its protection. Bob ... presents a check to the Delaware Highlands Conservancy for ... program. The small $2-per-stay donations add up fast, as ... of the Upper Delaware River Region. , The Kiesendahl ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... , ... ... ... ...
... to physical function but also extend to neurological function, according ... Journals of Gerontology Series A: Biological and Medical Sciences ... collection of ten articles highlighting new findings related to obesity ... of improved medical management of cardiovascular disease is that many ...
... procedures annually may improve life expectancy, study finds ... with both mammography and MRI appears to be a ... high risk for breast cancer, U.S. researchers say. , ... at Massachusetts General Hospital in Boston, and colleagues used ...
... physician shortages, researchers say, , TUESDAY, Feb. 23 (HealthDay News) -- ... a sharp decline in the average number of hours they work ... 1996, the average work week of doctors remained steady, but between ... work dropped nearly four hours a week -- from 54.9 to ...
... ... ... , ... , , , ...
... ... ... ... , ...
Cached Medicine News:Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 2Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 3Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 4Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 5Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 6Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 7Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2Health News:Mammogram Plus MRI Cost-Effective in High-Risk Women 2Health News:Doctors Working Less, Earning Less 2Health News:Doctors Working Less, Earning Less 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 2Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 4Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 5Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 2Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 3
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
The pediatric blanket provides full coverage for pediatric patient care. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also red...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Medicine Products: